| Revista: | Archivos venezolanos de farmacología y terapéutica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000326297 |
| ISSN: | 0798-0264 |
| Autores: | Paredes, C1 Chávez, E2 Cristians, G2 Rondón, J.C2 Ramírez, A2 Márquez, M.A |
| Instituciones: | 1Centro Clínico Profesional, Caracas, Distrito Federal. Venezuela 2Hospital Luis Gómez López, Barquisimeto, Lara. Venezuela |
| Año: | 2009 |
| Periodo: | Ene |
| Volumen: | 28 |
| Número: | 1 |
| Paginación: | 43-47 |
| País: | Venezuela |
| Idioma: | Español |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, caso clínico |
| Resumen en español | adversos (somnolencia, elevación discreta de la presión arterial). En el grupo de NC tres pacientes presentaron efectos adversos (somnolencia con lipotímia, cefalea acompañada con alergia, taquicardia), ninguno de estos efectos determinó la suspensión del tratamiento. Conclusiones: Ambos productos resultaron efectivos y bien tolerados en el tratamiento del vértigo de origen periférico |
| Resumen en inglés | Vertigo is a symptom that is characterized by the illusion of movement. It affects both individual welfare and the ability to perform activities of daily living, having a negative impact on quality of life, so it is important to find a comfortable and effective therapy that allows the patient to join the work of the daily life as soon as possible and with the best quality of life. Methods: We evaluated the effectiveness in the treatment of vertigo of peripheral origin of two formulations of nimodipine: conventional nimodipine of administration three times daily (30 mg Nimotop®) versus nimodipine 90 mg. Extender Release (ER) administration once day (ER Tropocer® 90 mg). We performed a prospective, randomized, double-blind, double dummy, national multicenter parallel-group, clinical study which included patients with vertigo of peripheral origin, defined as a score greater than or equal to 7 at the Vertigo-dizziness Differential Diagnosis Score (VDDDS). Patients were evaluated with the scale Index of Severity of Vertigo and Vestibular Disability Index. Results: In the nimodipine ER group, the index of severity of vertigo decreased 50%: in 38% of patients to 14 days in 53% and 92% at 4 and 8 weeks respectively. The vestibular disability index decreased 50% to 14 days in 31% of patients and in 77% and 92% at 4 and 8 weeks respectively. In the nimodipine Conventional group, the index of severi-ty of vertigo decreased in 50% in 25% of patients to 14 days in 67% and 93% at 4 and 8 weeks respectively. The disability vestibular index decreased 50% to 14 days in 30% of patients and in 78% and 100% at 4 and 8 weeks respectively, without significant differences between groups. In the NER group, two patients experienced side effects (drowsiness, discreet elevation in blood pressure). In the NC group three patients had adverse effects (drowsiness with fainting, accompanied with allergy, headache, tachycardia, none of these effects to determine the suspension of.. |
| Disciplinas: | Medicina |
| Palabras clave: | Farmacología, Neurología, Nimodipina, Liberación prolongada, Vértigo, Eficacia |
| Keyword: | Medicine, Neurology, Pharmacology, Nimodipine, Prolonged release, Dizziness, Efficacy |
| Texto completo: | Texto completo (Ver PDF) |
